| abstract |
Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of disorders associated with NMDA receptor activity, including neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: Formula I wherein: each (L)k-Arl is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NRI or 0 and each RI and R2 is independently H, alkyl, alkenyl or aralkyl or RI and R2 taken together form a 5-8 membered ring; R3 R6 are selected from certain specific substituents or a carbonyl; Y is a bond, 0, S, SO, 502, CH2, NH, N(alkyl), or NHC(=0); and Z is OH, NR6R7, NR8S02(alkyl), NR8C(0)NR6R7, NR8C(0)0(alkyl), NR8- dihydrothiazole, or NR8-dihydroimidazole or wherein Z can fuse with Ar2 to form selected heterocycles.Formula (I) |